In addition to virulence factors that disrupt the humoral immune response and thus require counteraction, bacterial IgA peptidases also hold therapeutic potential by degrading pathogenic IgA excess or deposits associated with conditions such as IgA nephropathy, vasculitis, myeloma, and linear dermatosis. The gene discussed is CD79A; the disease is IgA glomerulonephritis.